Related Experiment Videos
Dexamethasone prevents virus-induced hyperresponsiveness via multiple mechanisms
Liliana Moreno1, David B Jacoby, Allison D Fryer
1Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Summary
Dexamethasone prevents viral infection-induced airway hyperresponsiveness and M2 muscarinic receptor dysfunction in guinea pigs. This corticosteroid treatment offers a potential therapeutic strategy for respiratory viral infections.
Area of Science:
- Respiratory Medicine
- Pharmacology
- Virology
Background:
- Neuronal M2 muscarinic receptors in the lungs normally inhibit acetylcholine release.
- Parainfluenza virus infection impairs M2 receptor function, leading to increased acetylcholine release and bronchoconstriction.
- Glucocorticoids are known to reduce airway hyperresponsiveness.
Purpose of the Study:
- To investigate if dexamethasone prevents virus-induced airway hyperresponsiveness and M2 receptor dysfunction.
- To evaluate the effects of low-dose (6.5 microg/kg) and high-dose (65 microg/kg) dexamethasone.
Main Methods:
- Guinea pigs were infected with parainfluenza virus.
- Bronchoconstriction was assessed using pilocarpine and vagal stimulation.
- M2 receptor function, airway hyperresponsiveness, viral load, and inflammation were measured.
- Dexamethasone was administered intraperitoneally.
Main Results:
- Virus-infected guinea pigs exhibited M2 receptor dysfunction and airway hyperresponsiveness.
- Low-dose dexamethasone ameliorated M2 dysfunction and reduced viral load without affecting inflammation.
- High-dose dexamethasone fully reversed M2 dysfunction, reduced viral titers and inflammation, and enhanced M2 function in uninfected animals.
Conclusions:
- Dexamethasone effectively prevents virus-induced airway hyperresponsiveness and M2 receptor dysfunction.
- The protective effects of dexamethasone involve multiple mechanisms, including viral load reduction and modulation of inflammation.
- High-dose dexamethasone demonstrates significant therapeutic potential in managing viral respiratory infections.